The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder

作者：Bing Cao, Caroline Park, Mehala Subramaniapillai, Yena Lee, Michelle Iacobucci, Rodrigo B. Mansur, Hannah Zuckerman, Lee Phan, Roger S. McIntyre · 发表于：Frontiers in Psychiatry · 年份：2019 · DOI：10.3389/fpsyt.2019.00017 · 被引用次数：143 · 研究领域：Treatment of Major Depression、Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes、Maternal Mental Health During Pregnancy and Postpartum

Background Anhedonia is a common, persistent and disabling phenomenon in treated adults with Major Depressive Disorder (MDD). Hitherto, relatively few antidepressant agents have been evaluated with respect to their effect on anhedonia in MDD. Methods This is a post-hoc analysis of a primary study that sought to evaluate the sensitivity to change of the THINC-integrated tool (THINC-it) in MDD (ClinicalTrials.gov Identifier: NCT03053362). Adults meeting DSM-5 criteria for MDD with at least moderate depressive symptom severity [i.e. Montgomery Åsberg Depression Rating Scale (MADRS) total score ≥ 20] were eligible. Subjects were recruited between October 2017 and August 2018 in Toronto, Ontario at the Brain and Cognition Discovery Foundation. All subjects received open-label vortioxetine (10-20 mg/day, flexibly-dosed) for 8 weeks. Herein, the primary outcome of interest was the change from baseline to endpoint in the Snaith-Hamilton Pleasure Scale (SHAPS) total score, as well as the MADRS anhedonia factor. The mediational effects of improvements in anhedonia on general function and quality of life, as measured by the Sheehan Disability Scale (SDS) and the 5-Item World Health Organization Well-Being Index (WHO-5), were secondarily assessed. Results A total of 100 subjects with MDD were enrolled in the primary study and began treatment with vortioxetine. Vortioxetine significantly improved anhedonia as evidenced by significant baseline to endpoint improvements in SHAPS and MADRS an...